News and Announcements
Insync Investment Success Featured on the Front Page of the Australian Financial Review
- Published February 19, 2020 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Insync Funds Management was recently featured on the front page of the Australian Financial Review. In the article titled “Dumping the rule book helps this manager succeed” the writer talks about Insync’s long track record of performance and how the firm concentrates on disruption, megatrends and having a future-focused process and philosophy. Recognition at this national level is due to the ongoing and accelerating marketing Insync has been doing to raise awareness of its brand and grow funds under management.
The article was over 1200 words across 3 sections of the Monday edition including a number of photos of Insync CIO, Monik Kotecha. To read the full article click here.
About Insync Funds Management Pty Ltd
Insync Funds Management Pty Ltd is a Sydney-based specialist future focused global equity funds management company established in 2009 that invests in a concentrated portfolio of highly profitable global stocks that have delivered superior returns for our fund investors over a sustained period of 10 years.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
